Subscribe to RSS
DOI: 10.1055/s-0039-1697953
Urokinase Plasminogen Activator Overexpression Reverses Established Lung Fibrosis
Funding Funding for this project was provided by NIH HL105489 and 141195 (to J.C.H.), HL078871 (to T.H.S.), HL108904 (to K.K.K.), HL092961 and HL133320 (to D.J.T.), and Department of Defense GW160154 (to J.J.O.).Publication History
09 March 2019
12 August 2019
Publication Date:
08 November 2019 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00035024/201912/lookinside/thumbnails/10-1055-s-0039-1697953_190125-1.jpg)
Abstract
Introduction Impaired plasminogen activation (PA) is causally related to the development of lung fibrosis. Prior studies demonstrate that enhanced PA in the lung limits the severity of scarring following injury and in vitro studies indicate that PA promotes matrix degradation and fibroblast apoptosis. These findings led us to hypothesize that increased PA in an in vivo model would enhance the resolution of established lung fibrosis in conjunction with increased myofibroblast apoptosis.
Methods Transgenic C57BL/6 mice with doxycycline inducible lung-specific urokinase plasminogen activator (uPA) expression or littermate controls were treated (day 0) with bleomycin or saline. Doxycycline was initiated on days 1, 9, 14, or 21. Lung fibrosis, stiffness, apoptosis, epithelial barrier integrity, and inflammation were assessed.
Results Protection from fibrosis with uPA upregulation from day 1 through day 28 was associated with reduced parenchymal stiffness as determined by atomic force microscopy. Initiation of uPA expression beginning in the late inflammatory or the early fibrotic phase reduced stiffness and fibrosis at day 28. Induction of uPA activity in mice with established fibrosis decreased lung collagen and lung stiffness while increasing myofibroblast apoptosis. Upregulation of uPA did not alter lung inflammation but was associated with improved epithelial cell homeostasis.
Conclusion Restoring intrapulmonary PA activity diminishes lung fibrogenesis and enhances the resolution of established lung fibrosis. This PA-mediated resolution is associated with increased myofibroblast apoptosis and improved epithelial cell homeostasis. These studies support the potential capacity of the lung to resolve existing scar in murine models.
-
References
- 1 Sisson TH, Simon RH. The plasminogen activation system in lung disease. Curr Drug Targets 2007; 8 (09) 1016-1029
- 2 Sisson TH, Hattori N, Xu Y, Simon RH. Treatment of bleomycin-induced pulmonary fibrosis by transfer of urokinase-type plasminogen activator genes. Hum Gene Ther 1999; 10 (14) 2315-2323
- 3 Sisson TH, Hanson KE, Subbotina N, Patwardhan A, Hattori N, Simon RH. Inducible lung-specific urokinase expression reduces fibrosis and mortality after lung injury in mice. Am J Physiol Lung Cell Mol Physiol 2002; 283 (05) L1023-L1032
- 4 Ikeda T, Hirose N, Koto H, Hirano H, Shigematsu N. Fibrin deposition and fibrinolysis in the pathogenesis of pulmonary fibrosis [in Japanese]. Nihon Kyobu Shikkan Gakkai Zasshi 1989; 27 (04) 448-451
- 5 Hart DA, Whidden P, Green F, Henkin J, Woods DE. Partial reversal of established bleomycin-induced pulmonary fibrosis by rh-urokinase in a rat model. Clin Invest Med 1994; 17 (02) 69-76
- 6 Günther A, Lübke N, Ermert M. , et al. Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits. Am J Respir Crit Care Med 2003; 168 (11) 1358-1365
- 7 Eitzman DT, McCoy RD, Zheng X. , et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996; 97 (01) 232-237
- 8 Hattori N, Degen JL, Sisson TH. , et al. Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. J Clin Invest 2000; 106 (11) 1341-1350
- 9 Courey AJ, Horowitz JC, Kim KK. , et al. The vitronectin-binding function of PAI-1 exacerbates lung fibrosis in mice. Blood 2011; 118 (08) 2313-2321
- 10 Osterholzer JJ, Christensen PJ, Lama V. , et al. PAI-1 promotes the accumulation of exudate macrophages and worsens pulmonary fibrosis following type II alveolar epithelial cell injury. J Pathol 2012; 228 (02) 170-180
- 11 Glasser SW, Hagood JS, Wong S, Taype CA, Madala SK, Hardie WD. Mechanisms of lung fibrosis resolution. Am J Pathol 2016; 186 (05) 1066-1077
- 12 Horowitz JC, Thannickal VJ. Mechanisms for the resolution of organ fibrosis. Physiology (Bethesda) 2019; 34 (01) 43-55
- 13 Thannickal VJ, Henke CA, Horowitz JC. , et al. Matrix biology of idiopathic pulmonary fibrosis: a workshop report of the national heart, lung, and blood institute. Am J Pathol 2014; 184 (06) 1643-1651
- 14 Zhou Y, Huang X, Hecker L. , et al. Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. J Clin Invest 2013; 123 (03) 1096-1108
- 15 Booth AJ, Hadley R, Cornett AM. , et al. Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation. Am J Respir Crit Care Med 2012; 186 (09) 866-876
- 16 Parker MW, Rossi D, Peterson M. , et al. Fibrotic extracellular matrix activates a profibrotic positive feedback loop. J Clin Invest 2014; 124 (04) 1622-1635
- 17 Dodi AE, Ajayi IO, Chang C. , et al. Regulation of fibroblast Fas expression by soluble and mechanical pro-fibrotic stimuli. Respir Res 2018; 19 (01) 91
- 18 Liu F, Lagares D, Choi KM. , et al. Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis. Am J Physiol Lung Cell Mol Physiol 2015; 308 (04) L344-L357
- 19 Horowitz JC, Rogers DS, Simon RH, Sisson TH, Thannickal VJ. Plasminogen activation induced pericellular fibronectin proteolysis promotes fibroblast apoptosis. Am J Respir Cell Mol Biol 2008; 38 (01) 78-87
- 20 Blackwell TS, Tager AM, Borok Z. , et al. Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. Am J Respir Crit Care Med 2014; 189 (02) 214-222
- 21 Jenkins RG, Moore BB, Chambers RC. , et al; ATS Assembly on Respiratory Cell and Molecular Biology. An Official American Thoracic Society Workshop Report: use of animal models for the preclinical assessment of potential therapies for pulmonary fibrosis. Am J Respir Cell Mol Biol 2017; 56 (05) 667-679
- 22 Raghu G, Rochwerg B, Zhang Y. , et al; American Thoracic Society; European Respiratory society; Japanese Respiratory Society; Latin American Thoracic Association. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 2015; 192 (02) e3-e19
- 23 Bauman KA, Wettlaufer SH, Okunishi K. , et al. The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice. J Clin Invest 2010; 120 (06) 1950-1960
- 24 Sisson TH, Ajayi IO, Subbotina N. , et al. Inhibition of myocardin-related transcription factor/serum response factor signaling decreases lung fibrosis and promotes mesenchymal cell apoptosis. Am J Pathol 2015; 185 (04) 969-986
- 25 Liu F, Mih JD, Shea BS. , et al. Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression. J Cell Biol 2010; 190 (04) 693-706
- 26 Sicard D, Fredenburgh LE, Tschumperlin DJ. Measured pulmonary arterial tissue stiffness is highly sensitive to AFM indenter dimensions. J Mech Behav Biomed Mater 2017; 74: 118-127
- 27 Yang J, Wheeler SE, Velikoff M. , et al. Activated alveolar epithelial cells initiate fibrosis through secretion of mesenchymal proteins. Am J Pathol 2013; 183 (05) 1559-1570
- 28 Osterholzer JJ, Olszewski MA, Murdock BJ. , et al. Implicating exudate macrophages and Ly-6C(high) monocytes in CCR2-dependent lung fibrosis following gene-targeted alveolar injury. J Immunol 2013; 190 (07) 3447-3457
- 29 Roussey JA, Viglianti SP, Teitz-Tennenbaum S, Olszewski MA, Osterholzer JJ. Anti-PD-1 antibody treatment promotes clearance of persistent cryptococcal lung infection in mice. J Immunol 2017; 199 (10) 3535-3546
- 30 Sisson TH, Hansen JM, Shah M. , et al. Expression of the reverse tetracycline-transactivator gene causes emphysema-like changes in mice. Am J Respir Cell Mol Biol 2006; 34 (05) 552-560
- 31 Blaauboer ME, Emson CL, Verschuren L. , et al. Novel combination of collagen dynamics analysis and transcriptional profiling reveals fibrosis-relevant genes and pathways. Matrix Biol 2013; 32 (7-8): 424-431
- 32 Raghow R, Lurie S, Seyer JM, Kang AH. Profiles of steady state levels of messenger RNAs coding for type I procollagen, elastin, and fibronectin in hamster lungs undergoing bleomycin-induced interstitial pulmonary fibrosis. J Clin Invest 1985; 76 (05) 1733-1739
- 33 Ashley SL, Sisson TH, Wheaton AK. , et al. Targeting inhibitor of apoptosis proteins protects from bleomycin-induced lung fibrosis. Am J Respir Cell Mol Biol 2016; 54 (04) 482-492
- 34 Hecker L, Logsdon NJ, Kurundkar D. , et al. Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance. Sci Transl Med 2014; 6 (231) 231ra47
- 35 Lagares D, Santos A, Grasberger PE. , et al. Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis. Sci Transl Med 2017; 9 (420) eaal3765
- 36 Chang W, Wei K, Jacobs SS, Upadhyay D, Weill D, Rosen GD. SPARC suppresses apoptosis of idiopathic pulmonary fibrosis fibroblasts through constitutive activation of beta-catenin. J Biol Chem 2010; 285 (11) 8196-8206
- 37 Zhou Y, Horowitz JC, Naba A. , et al. Extracellular matrix in lung development, homeostasis and disease. Matrix Biol 2018; 73: 77-104
- 38 Idell S, James KK, Levin EG. , et al. Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J Clin Invest 1989; 84 (02) 695-705
- 39 Prabhakaran P, Ware LB, White KE, Cross MT, Matthay MA, Olman MA. Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Am J Physiol Lung Cell Mol Physiol 2003; 285 (01) L20-L28
- 40 Lazar MH, Christensen PJ, Du M. , et al. Plasminogen activator inhibitor-1 impairs alveolar epithelial repair by binding to vitronectin. Am J Respir Cell Mol Biol 2004; 31 (06) 672-678
- 41 Chapman HA, Allen CL, Stone OL. Abnormalities in pathways of alveolar fibrin turnover among patients with interstitial lung disease. Am Rev Respir Dis 1986; 133 (03) 437-443
- 42 Idell S, James KK, Gillies C, Fair DS, Thrall RS. Abnormalities of pathways of fibrin turnover in lung lavage of rats with oleic acid and bleomycin-induced lung injury support alveolar fibrin deposition. Am J Pathol 1989; 135 (02) 387-399
- 43 Hattori N, Mizuno S, Yoshida Y. , et al. The plasminogen activation system reduces fibrosis in the lung by a hepatocyte growth factor-dependent mechanism. Am J Pathol 2004; 164 (03) 1091-1098
- 44 Ho-Tin-Noé B, Meilhac O, Rossignol P, Lijnen HR, Anglés-Cano E. Dual effect of apolipoprotein(a) on plasmin(ogen)-induced apoptosis through modulation of cell detachment of adherent cells. Thromb Haemost 2006; 95 (01) 142-150
- 45 Rossignol P, Ho-Tin-Noé B, Vranckx R. , et al. Protease nexin-1 inhibits plasminogen activation-induced apoptosis of adherent cells. J Biol Chem 2004; 279 (11) 10346-10356
- 46 Kochtebane N, Choqueux C, Passefort S. , et al. Plasmin induces apoptosis of aortic valvular myofibroblasts. J Pathol 2010; 221 (01) 37-48
- 47 Crestani B, Marchand-Adam S, Quesnel C. , et al. Hepatocyte growth factor and lung fibrosis. Proc Am Thorac Soc 2012; 9 (03) 158-163
- 48 Schuliga M, Jaffar J, Harris T, Knight DA, Westall G, Stewart AG. The fibrogenic actions of lung fibroblast-derived urokinase: a potential drug target in IPF. Sci Rep 2017; 7: 41770
- 49 Izbicki G, Segel MJ, Christensen TG, Conner MW, Breuer R. Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol 2002; 83 (03) 111-119
- 50 Bakowska J, Adamson IY. Collagenase and gelatinase activities in bronchoalveolar lavage fluids during bleomycin-induced lung injury. J Pathol 1998; 185 (03) 319-323
- 51 Schiller HB, Fernandez IE, Burgstaller G. , et al. Time- and compartment-resolved proteome profiling of the extracellular niche in lung injury and repair. Mol Syst Biol 2015; 11 (07) 819
- 52 Cleveland ZI, Zhou YM, Akinyi TG. , et al. Magnetic resonance imaging of disease progression and resolution in a transgenic mouse model of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2017; 312 (04) L488-L499
- 53 Georges PC, Hui JJ, Gombos Z. , et al. Increased stiffness of the rat liver precedes matrix deposition: implications for fibrosis. Am J Physiol Gastrointest Liver Physiol 2007; 293 (06) G1147-G1154
- 54 Hinz B. Mechanical aspects of lung fibrosis: a spotlight on the myofibroblast. Proc Am Thorac Soc 2012; 9 (03) 137-147
- 55 Rubin JM, Horowitz JC, Sisson TH, Kim K, Ortiz LA, Hamilton JD. Ultrasound strain measurements for evaluating local pulmonary ventilation. Ultrasound Med Biol 2016; 42 (11) 2525-2531
- 56 Sáez-Royuela F, Linares P, Cervera LA. , et al; Castile and Leon Hepatology Association (ACyLHE). Evaluation of advanced fibrosis measured by transient elastography after hepatitis C virus protease inhibitor-based triple therapy. Eur J Gastroenterol Hepatol 2016; 28 (03) 305-312
- 57 Dillman JR, Stidham RW, Higgins PD. , et al. Ultrasound shear wave elastography helps discriminate low-grade from high-grade bowel wall fibrosis in ex vivo human intestinal specimens. J Ultrasound Med 2014; 33 (12) 2115-2123
- 58 Stidham RW, Xu J, Johnson LA. , et al. Ultrasound elasticity imaging for detecting intestinal fibrosis and inflammation in rats and humans with Crohn's disease. Gastroenterology 2011; 141 (03) 819-826